Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
21.18
-0.24 (-1.12%)
At close: Feb 27, 2026, 4:00 PM EST
21.35
+0.17 (0.80%)
After-hours: Feb 27, 2026, 6:00 PM EST
Denali Therapeutics Employees
Denali Therapeutics had 517 employees as of September 30, 2025. The number of employees increased by 127 or 32.56% compared to the same quarter last year.
Employees
517
Change
127
Growth
32.56%
Revenue / Employee
n/a
Profits / Employee
-$991,373
Market Cap
3.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 517 | 127 | 32.56% |
| Jun 30, 2025 | 486 | 122 | 33.52% |
| Mar 31, 2025 | 443 | 68 | 18.13% |
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Sep 30, 2024 | 390 | -57 | -12.75% |
| Jun 30, 2024 | 364 | -74 | -16.89% |
| Mar 31, 2024 | 375 | -55 | -12.79% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Sep 30, 2023 | 447 | 34 | 8.23% |
| Jun 30, 2023 | 438 | 43 | 10.89% |
| Mar 31, 2023 | 430 | 50 | 13.16% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Sep 30, 2022 | 413 | 53 | 14.72% |
| Jun 30, 2022 | 395 | 61 | 18.26% |
| Mar 31, 2022 | 380 | 69 | 22.19% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Sep 30, 2021 | 360 | 79 | 28.11% |
| Jun 30, 2021 | 334 | 58 | 21.01% |
| Mar 31, 2021 | 311 | 50 | 19.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 685 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Vera Therapeutics | 224 |
| Alumis | 223 |
DNLI News
- 3 days ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 23 days ago - Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript - Seeking Alpha
- 24 days ago - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - GlobeNewsWire
- 27 days ago - Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - GlobeNewsWire
- 4 weeks ago - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - GlobeNewsWire
- 6 weeks ago - Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewsWire
- 2 months ago - Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment - Seeking Alpha